16 September 2026 editorial review · Trial
Semaglutide with AID: randomized crossover trial: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: New historical crossover RCT:28 randomized, 24 completed; time in range +4.8 percentage points,two euglycemic ketosis episodes. Full paper clarifies one severe event during placebo titration; no severe event on semaglutide. Abstract shorthand not treated as entire-trial safety.
Registry: NCT05205928; COMPLETED; updated 2025-01-22; enrollment 28 (ACTUAL); results not posted.
Endpoint comparison: Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo) (4 weeks).
Sources for this record: Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care (NCT05205928) (registry); Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.